S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

DARE Dare Bioscience Inc

3.37

0.15 (4.66%)

After Hours

Last Updated: 23:00:05

Delayed by 15 minutes

Form D - Notice of Exempt Offering of Securities

Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Dare Bioscience Charts.

Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Dare Bioscience Charts.

Dare Bioscience Inc News

Form 8-K - Current report
Monday 16 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
Monday 16 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Tuesday 10 December 2024 (4 weeks ago) • GlobeNewswire Inc.

Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Wednesday 4 December 2024 (1 month ago) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Tuesday 26 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Tuesday 26 November 2024 (1 month ago) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Friday 15 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
Thursday 14 November 2024 (2 months ago) • GlobeNewswire Inc.

Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
Wednesday 13 November 2024 (2 months ago) • GlobeNewswire Inc.

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024
Thursday 7 November 2024 (2 months ago) • GlobeNewswire Inc.

More Dare Bioscience Inc News Articles

Lehman Brothers Financial (CE)

Kraig Biocraft Laborator... (QB)

Anavex Life Sciences

Elite Pharmaceuticals (QB)

Fannie Mae (QB)

Northwest Biotherapeutics (QB)

Bioelectronics (PK)

Decentral Life (PK)

Digital Brand Media and ... (PK)

Lightwave Logic

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions